Tai'en Kang released its 2026 interim report, with net profit attributable to the parent company of 3.7202 million yuan, a decrease of 89.97% compared with the same period last year. The company's total operating revenue was 320 million yuan, down 7.72% year-on-year; net cash inflow from operating activities was 54.2715 million yuan, an increase of 94.6513 million yuan compared with the same period last year. The company's latest asset-liability ratio was 32.35%, gross margin was 56.14%, ROE was 0.23%, and diluted earnings per share was 0.01 yuan.
Guangdong Taienkang Pharmaceutical Co. LtdNet profit down 89.97% year-on-year in interim report